Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1691-1700 of 1,873) with videos related to

Pageof 188
Sort By:
Journal of the American College of Cardiology|January 15, 2025
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFShingo Matsumoto, Pardeep S Jhund, Alasdair D Henderson, et al.
JAMA Cardiology|November 17, 2024
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialMisato Chimura, Xiaowen Wang, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.
European Heart Journal|September 11, 2019
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
JACC. Heart Failure|December 1, 2022
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert PanelMitchell A Psotka, William T Abraham, Mona Fiuzat, et al.
Journal of the American College of Cardiology|December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection FractionMikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2019
Chemical disarming of isoniazid resistance in <i>Mycobacterium tuberculosis</i>Kelly Flentie, Gregory A Harrison, Hasan Tükenmez, et al.
Circulation. Heart Failure|February 22, 2023
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort StudyNiklas Dyrby Johansen, Muthiah Vaduganathan, Deewa Zahir, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Pageof 188

Showing results (1691-1700 of 1,873) with videos related to

Sort By:
Pageof 188
Journal of the American College of Cardiology|January 15, 2025
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFShingo Matsumoto, Pardeep S Jhund, Alasdair D Henderson, et al.
JAMA Cardiology|November 17, 2024
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialMisato Chimura, Xiaowen Wang, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.
European Heart Journal|September 11, 2019
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
JACC. Heart Failure|December 1, 2022
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert PanelMitchell A Psotka, William T Abraham, Mona Fiuzat, et al.
Journal of the American College of Cardiology|December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection FractionMikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2019
Chemical disarming of isoniazid resistance in <i>Mycobacterium tuberculosis</i>Kelly Flentie, Gregory A Harrison, Hasan Tükenmez, et al.
Circulation. Heart Failure|February 22, 2023
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort StudyNiklas Dyrby Johansen, Muthiah Vaduganathan, Deewa Zahir, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Pageof 188